Quick Answer
WEST PHARMACEUTICAL SERVICES INC reported Operating Income Loss of $584.90 million for the year ending 2025.
- WEST PHARMACEUTICAL SERVICES INC showed an increase of +2.6% in Operating Income Loss from 2024 to 2025.
- This data is from WEST PHARMACEUTICAL SERVICES INC's annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 18 years of available data (2008 to 2025), WEST PHARMACEUTICAL SERVICES INC's Operating Income Loss has grown by 371.3%.
- Historical annual values: Fiscal year 2025: $584.90 million | Fiscal year 2024: $569.90 million | Fiscal year 2023: $676.00 million | Fiscal year 2022: $734.00 million | Fiscal year 2021: $752.30 million | Fiscal year 2020: $406.90 million | Fiscal year 2019: $296.60 million | Fiscal year 2018: $240.30 million | Fiscal year 2017: $225.80 million | Fiscal year 2016: $195.20 million | Fiscal year 2015: $128.60 million | Fiscal year 2014: $182.00 million | Fiscal year 2013: $162.40 million | Fiscal year 2012: $135.10 million | Fiscal year 2011: $109.60 million | Fiscal year 2010: $90.70 million | Fiscal year 2009: $97.50 million | Fiscal year 2008: $124.10 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: